SuperworthImpact Biomedical IBO
- Market cap
- $388.2M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $7K | $18K | n/a | $7K | $3K−57% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $1K | $1K | n/a | n/a | $1K+0% |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $6K | $17K | n/a | n/a | $2K−67% |
| R&D | $357K+8% | $630K+21% | $183K+2% | $121K−55% | $82K−77% | n/a | $103K−44% | $75K−38% | $52K−37% | n/a | $46K−55% | $76K+1% |
| SG&A | $101K+12% | $133K+241% | $148K+270% | $145K+254% | $132K+31% | n/a | $248K+68% | $246K+70% | $261K+98% | n/a | $1.6M+553% | $167K−32% |
| −$1.1M+21% | −$1.1M+10% | −$771K−4% | −$626K−38% | −$1.1M+5% | n/a | −$1M+31% | −$1.2M+84% | −$948K−16% | n/a | −$2.3M+127% | −$702K−39% | |
| Interest expense | $102K+11% | $125K+26% | $230K+128% | $261K+125% | $305K+199% | n/a | $271K+18% | $260K−0% | $262K−14% | n/a | n/a | n/a |
| Pre-tax income | −$1.2M+20% | −$1.3M−76% | −$998K+18% | −$884K−21% | $4.2M | n/a | −$1.3M+28% | −$14.4M+1524% | −$1.5M | n/a | −$2.3M+79% | −$700K−95% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$1.2M−48% | −$1.2M−63% | −$962K+13% | −$889K−19% | $4.2M | −$27.1M+2095% | −$1.3M+32% | −$14.3M+1514% | −$1.5M | $5.2M | −$2.3M+81% | −$699K−95% |
| −$0.02−33% | −$0.04−20% | −$0.10+900% | −$0.09+350% | $0.06 | n/a | −$0.11+10% | −$1.18+1211% | −$0.12 | n/a | −$0.02−82% | −$0.01−99% | |
| 70.5M+0% | 29.8M−58% | 10M−86% | 10M−86% | n/a | n/a | 12.1M+21% | 12.2M+22% | n/a | n/a | 107.8M+794% | 107.8M+785% |
Revenue: Q1 FY22: 6 months less the 3 months printed beside them.
Gross profit: 3 periods, Q2 FY25 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
SG&A: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Operating income: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY22: 6 months less the 3 months printed beside them.
Net income: Q1 FY22: 6 months less the 3 months printed beside them.
EPS, diluted: 3 periods, Q1 FY22 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22: share-days: the 6-month average less the second quarter's. 13 periods, Q2 FY22 to Q2 FY26: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Impact Biomedical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IBOImpact Biomedical | $388.2M | n/m | n/a | n/m | n/m | n/m | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on Impact Biomedical
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .